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Abstract

In an effort to probe Co(II) binding to metallo-β-lactamase CcrA, EPR, EXAFS, and 1H NMR studies were
conducted on CcrA containing 1 equiv (1-Co(II)-CcrA) and 2 equiv (Co(II)Co(II)-CcrA) of Co(II). The EPR spectra of
1-Co(II)-CcrA and Co(II)Co(II)-CcrA are distinct and indicate 5/6-coordinate Co(II) ions. The EPR spectra also
reveal the absence of significant spin-exchange coupling between the Co(II) ions in Co(II)Co(II)-CcrA. EXAFS
spectra of 1-Co(II)-CcrA suggest 5/6-coordinate Co(II) with two or more histidine ligands. EXAFS spectra of
Co(II)Co(II)-CcrA also indicate 5/6 ligands at a similar average distance to 1-Co(II)-CcrA, including an average of
about two histidines per Co(II). 1H NMR spectra for 1-Co(II)-CcrA revealed seven paramagnetically shifted
resonances, three of which were solvent-exchangeable, while the NMR spectra for Co(II)Co(II)-CcrA showed at
least 16 shifted resonances, including an additional solvent-exchangeable resonance and a resonance at 208
ppm. The data indicate sequential binding of Co(II) to CcrA and that the first Co(II) binds to the consensus
Zn1 site in the enzyme.

Enzymes that hydrolyze β-lactam- containing antibiotics, such as penicillins, cephalosporins, and carbapenems,
are called β-lactamases, and the production of β-lactamases by bacteria is the most common way that bacteria
become antibiotic-resistant. Since β-lactam-containing compounds account for almost 50% of the available,
effective antibiotics used in the clinic (1−3), bacterial resistance to these compounds is a serious public health
issue. There are currently over 300 known β-lactamases, and several attempts have been made to classify these
enzymes into four distinct groups based on molecular properties (4−9). Groups A, C, and D (or 1, 2, and 4) are
similar in that these enzymes utilize an active site serine as a nucleophile in the hydrolysis reaction. The
remaining group (B or 3) is often called metallo-β-lactamases (MβL's)1 because the enzymes require 1−2 Zn(II)
ions for full catalytic activity (5, 10−13. MβL's constitute an ever-growing and troubling class of β-lactamases
that have been found in clinical isolates of Bacillus anthracis, Pseudomonas aeruginosa, Klebsiella pneumoniae,
and several other pathogens (10−14). MβL's contain 1−2 mol of Zn(II)/mol of enzyme, hydrolyze all known
cephalosporins, carbapenems, and penicillins, are not inhibited by clavulanic acid and other classical βlactamase inhibitors, and have no known clinically useful inhibitor toward them.
Previous studies have shown that there is significant structural and mechanistic diversity among the MβL's,
leading to the grouping of the enzymes into three distinct subclasses (15) based on amino acid sequence identity
at the Zn(II) binding sites. The B1 enzymes have a Zn1 site consisting of His116, His118, and His196 and a Zn2 site
consisting of Asp120, Cys221, and His263 and are represented by metallo-β-lactamase CcrA from Bacteroides
fragilis (16) (Figure 1), the B2 enzymes have the same metal binding sites as the B1 enzyme except that His116 is
replaced by an Asn and are represented by metallo-β-lactamase ImiS from Aeromonas sobria (17), and the B3
enzymes have the same metal binding sites as the B1 enzymes except Cys221 is replaced with His121 and are
represented by metallo-β-lactamase L1 from Stenotrophomonas maltophilia (18). The structural diversity among

the MβL's suggests that one inhibitor may not be effective in treating infections caused by bacteria that produce
a metallo-β-lactamase. To address this question, we are currently characterizing a metallo-β-lactamase from
each of the group B subgroups (CcrA, ImiS, and L1) in an effort to identify common structural/mechanistic
properties of the enzymes toward which a single inhibitor can be designed.

Figure 1 Active site structure of CcrA (16). The small sphere labeled W1 is a bridged hydroxide/water ligand, and
W2 is a terminally bound water ligand. The figure was prepared using Rasmol version 2.7 (R. Sayle, 1994,
Greenford, Middlesex, U.K.) and the crystal coordinates of CcrA (PDB code 1ZNB).
There is considerable information available on MβL's, such as X-ray crystal structures (18−21) and spectroscopic,
mechanistic, (22−30), and computational studies (31−38). Nonetheless, there are long-standing questions about
the MβL's dealing with substrate binding, reaction mechanism, and the number of metal ions in the
physiologically relevant enzymes. We are currently using rapid freeze-quench spectroscopic studies to probe
substrate binding and the mechanism of L1 and ImiS. Before these studies can be performed on CcrA, detailed
spectroscopic characterization of the resting form of the enzyme is necessary. This work describes our efforts to
characterize cobalt binding to CcrA by using spectroscopic methods.

Experimental Procedures
Materials
Escherichia coli strain BL21(DE3) was obtained from Novagen, Madison, WI. The overexpression plasmid for
CcrA, pMSZ02, was generously supplied by Wang and Benkovic (26). Isopropyl β-d-thiogalactoside (IPTG) was
purchased from Anatrace (Maumee, OH). A Minitan II concentrator system was purchased from Fisher Scientific,
Pittsburgh, PA, and was equipped with four 10000 NMWL plates from Millipore, Bedford, MA. Protein solutions
were concentrated with an Amicon ultrafiltration cell equipped with YM-10 DIAFLO membranes from Amicon,
Inc., Beverly, MA. Dialysis tubing was prepared using Spectra/Por-regenerated cellulose molecular porous
membranes with a molecular mass cutoff of 6000−8000 Da.
Metal-free buffers were prepared by treatment of buffers with Chelex 100 resin, purchased from Bio-Rad
Laboratories, and filtration of the buffer through a 0.22 μm membrane from Osmonics, Inc. A fast protein liquid
chromatography (FPLC) system and Q-Sepharose chromatography columns were purchased from Amersham
Pharmacia Biotech. Nitrocefin was purchased from Becton Dickinson, and solutions of nitrocefin were filtered
through a Fisherbrand 0.45 μm syringe filter. All buffers and media were prepared using Barnstead NANOpure
ultrapure water.

Methods
Preparation of Co(II)-Substituted CcrA.
Soluble CcrA was overexpressed and purified according to Wang and Benkovic (26). Protein concentrations were
determined by using ε280 nm = 39000 M-1 cm-1 and Beer's law. Apo-CcrA was prepared by dialyzing purified CcrA
(0.4−0.5 mM) versus 3 × 1 L of 50 mM Hepes, pH 7.6, containing 10 mM EDTA, at 4 °C (12 h for each dialysis
step). The use of phenanthroline, in place of EDTA, resulted in precipitation of CcrA. The chelating agent was
removed by dialysis versus 8 × 1 L of metal-free, 50 mM Hepes, pH 7.6, at 4 °C. Metal analyses of the resulting
enzyme solutions were used to verify that the enzymes contain <0.05 equiv of Zn(II). Apo-CcrA can be stored
indefinitely at −70 °C after flash freezing in liquid nitrogen.
To prepare 1-Co(II)-CcrA, stoichiometric amounts of Co(II) were added directly to apo-CcrA. The rapid addition of
highly concentrated CoCl2 stocks to highly concentrated (>1 mM) apo-CcrA samples resulted in immediate
precipitation of the protein. To circumvent this problem, NMR and EPR samples were prepared by slowly adding
aliquots of CoCl2 to relatively dilute solutions of apo-CcrA (∼300 μM). After 30 min incubations on ice, the CcrA
samples were concentrated using a Centricon-10. During the preparation of EXAFS samples, the CcrA samples
contained 20% (v/v) glycerol, and the addition of Co(II) to concentrated samples of apo-CcrA with glycerol did
not result in precipitated protein. The EXAFS samples exhibited the same steady-state kinetic constants as the
NMR and EPR samples. Preparation of Co(II)-substituted CcrA was performed in a glovebox under a nitrogen
atmosphere. To prepare a Co(II)Co(II) form of CcrA, a second equivalent of Co(II) was added to 1-Co(II)-CcrA, and
the sample was incubated at least 30 min before analysis.

Metal Analysis and Steady-State Kinetics.
The metal content of protein solutions was determined using a Varian Liberty 150 inductively coupled plasma
spectrometer with atomic emission spectroscopy detection (ICP-AES). The protein samples were diluted to 10
μM with 50 mM Hepes, pH 7.6. A calibration curve with four standards and a correlation coefficient of greater
than 0.999 was generated using Zn and Co reference solutions from Fisher Scientific. The following emission
wavelengths were chosen to ensure the lowest detection limits possible: Zn, 213.856 nm, and Co, 238.892 nm.
Enzyme activity was determined in MTEN buffer (50 mM Mes, 25 mM Tris, 25 mM ethanolamine, and 100 mM
NaCl) at pH 7.0 and 25 °C using nitrocefin as substrate. The formation of the hydrolyzed nitrocefin was
monitored at 485 nm, and absorbance data were converted into concentration data by using an extinction
coefficient of ε485nm = 17400 M-1 cm-1.

EPR Spectroscopy.
EPR spectra were recorded using a Bruker E500 EleXsys spectrometer equipped with an Oxford Instruments ESR900 helium flow cryostat and a Bruker DM 4116 ER cavity operating at 9.6330 ± 0.0005 GHz. Data were collected
at 12 K with 2 mW microwave power and 10.6 G magnetic field modulation at 100 kHz; these conditions were
determined to be nonsaturating. Spectra were simulated by using XSophe simulation software (Bruker Biospin)
and the spin Hamiltonian H = βgHS + SDS, explicitly assuming S = 3/2. EPR samples were made by pipetting 400 μL
of ca. 400 μM Co(II)-substituted CcrA into a 4 mm o.d. quartz EPR tube. Samples were prepared under a nitrogen
environment in a glovebox, and the samples were frozen by slow immersion in a liquid nitrogen bath.

EXAFS Spectroscopy.
CcrA samples (1−2 mM) for EXAFS were prepared with 20% (v/v) glycerol as glassing agent, preloaded in Lucite
cuvettes with 6 μm polypropylene windows, and frozen in liquid nitrogen. X-ray absorption spectra for 1-Co(II)
and Co(II)Co(II) analogues of CcrA were measured on two individually prepared samples. As both samples gave
comparable results, the two data sets for each analogue were averaged, and the averaged data are presented in
Figure 3 (15 scans per sample). XAS data were measured at the National Synchrotron Light Source (NSLS),

beamline X9B, using a Si(111) double crystal monochromator; data collection and reduction were performed
according to published procedures (39), using E0 = 7725 eV. The resulting EXAFS data were fitted (∼9 deg of
freedom for single-scattering and 30 for multiple-scattering models; see Table 1) using the nonlinear leastsquares algorithm contained in the program IFEFFIT, interfaced with “SixPack” (available free of charge
from http://www-ssrl.slac.stanford.edu/∼swebb/index.htm). The scale factor, Sc, and ΔE0 were calibrated by
fitting data for compounds of known structure, holding all other parameters fixed. Models used for calibration
were bis[tris(pyrazolylborate)]cobalt(II), CoTp2, for Co−N scattering and (tetramesitylthiolate)cobalt(II),
Co(Smes)4, for Co−S interactions. Optimum scale factors and ΔE0's were Co−N, Sc = 0.74, ΔE0 = −11, and
Co−S, Sc = 0.85, ΔE0 = −11.
Fits were carried out for all reasonable coordination numbers, holding Sc and ΔE0 constant, while varying Ras, and
σas2. Multiple-scattering fits were performed according to published procedures (40), utilizing the pyrazole outer
shell scattering of CoTp2 for calibration. Briefly, multiple-scattering contributions were approximated by fitting
FEFF calculated paths, derived from the crystallographic coordinates of CoTp2, to the experimental EXAFS of
CoTp2. The best fits resulted in four prominent multiple-scattering features (representing 140 total scattering
paths), and paths of similar overall length were combined to match these four features. Consequently, the labels
in Table 1, while reflecting the greatest contributor to a combined path, are nonphysical. These combined paths
were used to fit protein data, fixing the number of imidazole ligands per cobalt ion at half-integral values while
varying Ras and σas2.

NMR Spectroscopy.
The samples for NMR studies were made by loading 1 mM Co(II)-substituted CcrA into a 5 mm Wilmad NMR
tube under a nitrogen environment in a glovebox. The buffer was Hepes, pH 7.0, containing ∼10% D2O. Samples
in 90% D2O were made by performing three or more dilution/concentration cycles in a Centricon-10. NMR
spectra were collected on a Bruker Avance 500 spectrometer operating at 500.13 MHz, 298 K, magnetic field of
11.7 T, recycle delay (AQ) of 41 ms, and sweep width of 400 ppm. Chemical shifts were referenced by assigning
the H2O signal the value of 4.70 ppm. A modified presaturation pulse sequence (zgpr) was used to suppress the
proton signals originating from solvent. The presaturation pulse was the shortest possible (500 ms) to avoid
saturation of solvent-exchangeable proton signals.

UV−Vis Spectrophotometry.
Apo-CcrA (360 μM) in 50 mM Hepes, pH 7.6, was titrated with an aqueous solution of CoCl2 (Strem Chemicals,
99.999% pure). After the solution was incubated on ice for 30 min, the absorbance spectra were obtained with
the buffer as a reference. UV−vis difference spectra were obtained by subtracting the spectrum of apo-CcrA
from those of the Co(II)-added samples.

Results
Preparation of Co(II)-Substituted CcrA.
Purified, as-isolated CcrA contained 1.7 equiv of Zn(II), which is consistent with metal analyses reported by
Yanchak et al. (25) and Yang et al. (41). Steady-state kinetic studies on multiple preparations of CcrA
demonstrated that the enzyme exhibits a kcat value of 221 s-1 and a Km of 6.2 μM when using nitrocefin as the
substrate. These steady-state kinetic values are similar to those reported by others (25, 26, 41−44. The steadystate kinetic constants kcat and Km for CcrA with 1 equiv of Co(II) added (1-Co(II)-CcrA) were 98 s-1 and 12 μM,
respectively, while CcrA with 2 equiv of Co(II) added (Co(II)Co(II)-CcrA) exhibited values of 110 s-1 and 5 μM,
respectively. These values are in excellent agreement with those previously published by Wang and Benkovic
(26).

EPR Spectroscopy.
The EPR spectrum of 1-Co(II)-CcrA was obtained at 12.4 K (Figure 2). This spectrum is essentially axial, with a
resolved geff(z), and was well-simulated by assuming S = 3/2, Ms = ±1/2, gx,y = 2.27, gz = 2.22, and E/D = 0.035
(Figure 2B). These simulation parameters are consistent with a 5- or 6-coordinate Co(II) center in 1-Co(II)-CcrA,
which is slightly distorted from axial symmetry. The EPR signal for 1-Co(II)-CcrA integrated to 1.0 equiv of Co(II).
The small derivative feature at 1630 G was due to a trace Fe(III) contaminant and integrated to ≤0.01 spin; this
was included in the simulation as an S = 5/2 component with extensive strains in D and E/D. The EPR spectrum of
Co(II)Co(II)-CcrA is different than that of 1-Co(II)-CcrA (Figure 2C) and integrates to 2.0 equiv Co(II). It appears to
be overlapping spectra of at least two distinct signals, one of which is the spectrum of 1-Co(II)-CcrA. Therefore,
the spectrum of 1-Co(II)-CcrA was subtracted from the spectrum of Co(II)Co(II)-CcrA, and the resulting difference
spectrum is shown in Figure 2E. The subtracted spectrum was simulated by assuming Ms = ±1/2, gx,y = 2.22, gz =
2.40, and E/D = 0.005 (Figure 2F). Summation of the simulated spectrum of 1-Co(II)-CcrA (Figure 2B) and the
simulated spectrum of the subtracted spectrum (Figure 2F) results in spectrum D (Figure 2), which is a good fit to
the experimental spectrum of Co(II)Co(II)-CcrA (Figure 2C). The EPR signal due to Co(II) in the second metal
binding site of Co(II)Co(II)-CcrA (Figure 2E) is also essentially axial, and the simulation parameters indicate 5- or
6-coordination geometry for the Co(II). The very broad nature of the spectral features and, particularly, the
unresolved geff(z) feature indicate a higher degree of conformational flexibility than for the first site, possibly due
to the binding of one or more solvent molecules. The distinct signals from Co1 and Co2 can be deconvoluted
from the spectrum of Co(II)Co(II)-CcrA, and there is no evidence for significant spin-exchange coupling between
the Co(II) ions in Co(II)Co(II)-CcrA.

Figure 2 Experimental and simulated EPR spectra of Co(II)-substituted CcrA. Co(II)-substituted CcrA
concentrations were 300 μM in 50 mM Hepes, pH 7.6. Experimental spectra are (A) 1-Co(II)-CcrA, (C) Co(II)Co(II)CcrA, and (E) [2Co − 1Co]-CcrA, and spectra B, D, and F are computer simulations of spectra A, C, and E,
respectively.

EXAFS Spectroscopy.
To further elucidate the structure of Co(II)-substituted CcrA, EXAFS data were collected for both 1-Co(II)- and
Co(II)Co(II)-CcrA. Fourier transforms (FTs, solid lines in Figure 3, left) of k3-weighted EXAFS data (solid lines in
Figure 3, right) are presented overlaid with the best fits (dotted lines); curve fitting results are summarized in
Table 1. The data for 1-Co(II)-CcrA (top half of Figure 3) were best fitted with a mixed first shell of two O (2.08 Å)
and three N (2.20 Å) ligands to Co(II). The average first-shell bond length is too long to be consistent with a 4coordinate cobalt ion. Inclusion of a sulfur ligand in the first shell leads to an increase in the fit residual,
indicating sulfur is not bound to the first equivalent of cobalt bound by CcrA. Multiple-scattering fits indicate 2.0
± 0.5 histidines bound to the Co(II) ion in 1-Co(II)-CcrA; the fit shown in the top half of Figure 3 corresponds to fit
3 in Table 1. A model that includes three similarly coordinated histidines gives a fit residual only 5% larger than
the two His model presented. The ordered outer shell scattering indicates well-ordered binding of the first Co(II)
ion to CcrA, and the data are most consistent with binding at the consensus Zn1 site.

Figure 3 Fourier transforms (left) of experimental EXAFS spectra (right) for 1-Co(II)CcrA (top) and Co(II)Co(II)CcrA
(bottom). Experimental data are presented as solid lines; fits are presented as open diamonds.

Table 1: EXAFS Curve Fitting Results for 1-Co-CcrA and Co(II)Co(II)-CcrAa
model
Co−N
Co−O
Co−S
Co−Hisb
Co−CCO2− Rfc Ru
1-Co(II)-CcrA
1 5 N/O
2.14 (5.1)
31 160
2 3N+2O
2.20 (6.6) 2.08 (1.8)
19 155
3 3 N + 2 O + 2 His
2.19 (5.3) 2.08 (3.0)
2.92 (31), 3.39 (11), 4.13 (14), 4.36 (9)
62 93
Co(II)Co(II)-CcrA
4 5 N/O
2.14 (7.7)
33 136
5 3N+2O
2.20 (4.1) 2.04 (1.4)
18 124
6 3 N + 2 O + 0.5 S
2.20 (0.5) 2.04 (0.1) 2.58 (19)
30 115
7 3 N + 2 O + 2.5 His
2.19 (2.0) 2.03 (0.9)
2.84 (15), 3.35 (18), 4.06 (12), 4.31 (10)
60 68
8 3 N + 2 O + 2.5 His + 1 CCO2− 2.20 (2.0) 2.03 (0.6)
2.99 (10), 3.33 (15), 4.05 (11), 4.31 (10) 2.48 (0.6) 44 53
a
Distances (Å) and disorder parameters [in parentheses, σ2 (10-3 Å2)] shown derive from integer or half-integer coordination number fits to filtered
EXAFS data: k = [1, 12.1]; R = [0.9, 2.2] for single-scattering fits, and R = [0.1, 4.3] for multiple-scattering fits.b Multiple-scattering paths represent the
combined paths described in Experimental Procedures. The labels indicate the individual path with largest amplitude, of those included in the combined
path.c Goodness of fit (Rf for fits to filtered data and Ru for fits to unfiltered data) is defined as 1000{[Re(χicalc)]2 + [Im(χicalc)]2}/{[Re(χiobs)]2 + [Im(χiobs)]2},
where N is the number of data points.

For Co(II)Co(II)-CcrA (Figure 3, bottom), the EXAFS data are best fitted with a 5-coordinate model that includes a
mixed first shell of two O (2.04 Å) and three N (2.20 Å) ligands per metal ion, similar to the result for 1-Co(II)CcrA. The outer shell scattering is significantly more ordered for Co(II)Co(II)-CcrA, consistent with the
lower E/D shown above for the second Co(II) ion bound by CcrA. Fits, summarized in Table 1, indicate an average
of 2.0 ± 0.5 histidines per Co(II) ion, similar to the number of coordinated histidines shown in the crystal
structure of Zn(II)Zn(II)-CcrA (16). A new feature at R + α of 2.1 Å can also be seen for Co(II)Co(II)-CcrA, and this
feature is adequately modeled with a single carbon atom at 2.48 Å, consistent with monodentate coordination
of Asp120 by the second cobalt ion.
Although we expect the presence of, on average, 0.5 sulfur ligand per metal ion, inclusion of a sulfur scatterer, in
either filtered first shell fits or multiple-scattering fits, does not significantly improve the fit residual (∼10%).
Attempts to fit the feature ascribed to a carboxylate carbon, above, with 0.5 sulfur atom led to an unreasonable
Co−S distance of >2.5 Å and an increase in the fit residual. Considering that the putative thiolate would comprise
just 10% of the average coordination sphere of a cobalt ion in Co(II)Co(II)-CcrA, together with the heterogeneity
indicated by first shell fits, and the overall complexity of the metal site, it may not be possible to detect the
expected sulfur ligand. EXAFS studies of 5-coordinate mononuclear Co compounds with mixed (N3OS)
coordination suggest that this may be the case over the limited k-range typically available for metalloproteins (A.
L. Costello and D. L. Tierney, unpublished results). A metal−metal scattering interaction at 3.60 Å could also be
included in fits to the Co(II)Co(II)-CcrA EXAFS data; however, its inclusion is not statistically justified (∼12%
improvement). While this may indicate that still higher quality data are required to determine the metal−metal
distance in this system, it is also consistent with the lack of a covalent bridge connecting the two metal ions.
Considering the lack of appreciable magnetic coupling between the cobalt ions, and the relatively high
coordination number indicated both by the EPR and by the first shell fits, we favor the latter interpretation.

NMR Spectroscopy.
The 1H NMR spectra of 1-Co(II)-CcrA and Co(II)Co(II)-CcrA are shown in panels A and B of Figure 4, respectively.
Duplicate spectra were also obtained for samples in buffer containing ∼90% D2O to identify any solventexchangeable protons. The spectrum of 1-Co(II)-CcrA has only seven hyperfine-shifted peaks (Figure 4). The
chemical shifts of these peaks are consistent with these resonances originating from protons of metal-bound
amino acid ligands. Among the seven peaks, three of them are solvent-exchangeable and can be assigned to
three NH protons of metal-bound histidines. The appearance of three solvent-exchangeable peaks is consistent
with the first Co(II) binding to the Zn1 site, which has three histidine residues (Figure 4). Unambiguous
assignment of the remaining four peaks in the NMR spectrum of 1-Co(II)-CcrA is difficult; however, they may be
from four β-CH2 protons of Co(II)-bound histidine residues. The most likely histidines are His116 and His196,
which bind to Co(II) through Nε2 (16). The signals of ortho protons of Co(II)-bound histidines and the two βCH2 protons of His118 may be broadened beyond detection due to their close proximity to the paramagnetic
center.

Figure 4 1H NMR spectra of Co(II)-substituted CcrA: (A) 1-Co(II)-CcrA and (B) Co(II)Co(II)-CcrA. The solventexchangeable proton signals are indicated by asterisks.
The NMR spectrum of Co(II)Co(II)-CcrA has 16 shifted peaks including the 7 peaks observed in the 1-Co(II)-CcrA
spectrum (Figure 4). The most important features in this spectrum are the appearance of an additional solventexchangeable peak at 65 ppm and a broad peak at 208 ppm. The presence of these peaks clearly demonstrates
that the second equivalent of Co(II) binds to a distinct site, and the additional solvent exchangeable resonance
strongly suggests that the second Co(II) is bound to the Zn2 site, which has only one histidine (Figure 1). Addition
of the second equivalent of Co(II) also alters the chemical shift of one of the solvent-exchangeable protons
identified for 1-Co(II)-CcrA (from 130 to 125 ppm), demonstrating a slight rearrangement of the metal site on
binding the second metal ion. However, Co(II) binding to the Zn2 site was expected to give rise to only six
additional peaks (two β-CH2 and an NH from His263 and two β-CH2 and the α-CH of Asp120) instead of the
additional nine peaks observed. A plausible explanation for this observation comes from the EXAFS and EPR
data. The EXAFS studies suggest 5- or 6-coordination for both Co(II) ions, and EPR also indicates that the two
Co(II) sites are either 5- or 6-coordinate. This larger coordination sphere, relative to native Zn(II) in Zn(II)Zn(II)CcrA, would result in an increased distance between the ortho protons of metal-bound histidines and the cobalt
ions in Co(II)Co(II)-CcrA and in the appearance of additional peaks.

UV−Vis Spectrophotometry.
The UV−vis difference spectra of CcrA containing 0.5, 1.0, and 2.0 equiv of Co(II) at pH 7.6 are shown in Figure 5.
Identical spectra were obtained at pHs of 6.0 and 7.0 (data not shown). The addition of 0.5 equiv of Co(II) to
apo-CcrA resulted in a broad signal between 450 and 650 nm, with an extinction coefficient of 65 M-1 cm-1. There
is no evidence for a S−Co(II) LMCT (expected peak position at 320−340 nm). The addition of 1.0 and 2.0 equiv of
Co(II) to apo-CcrA resulted in increases in the broad feature between 450 and 650 nm, and the extinction
coefficient of the feature increased from 90 M-1 cm-1 [CcrA with 1 equiv of Co(II)] to 114 M-1 cm-1 [CcrA with 2
equiv of Co(II)]. In the spectrum of CcrA containing 2.0 equiv of Co(II), there does appear to be a small feature at
330 nm (see arrow in Figure 5); however, the low signal-to-noise ratio in the spectrum prevents an unequivocal
assertion that this signal is due to a S to Co(II) LMCT. The addition of 3.0 equiv or more of Co(II) to apo-CcrA
resulted in rapid formation of a precipitate. In addition, spectrophotometric titrations of concentrated samples
of apo-CcrA (>500 μM) resulted in rapid precipitation of the enzyme.

Figure 5 Spectrophotometric titration of apo-CcrA with Co(II). Apo-CcrA (360 μM) in 50 mM Hepes, pH 7.6, was
titrated with 0.5, 1.0, and 2.0 equiv of Co(II). The spectrum of apo-CcrA was subtracted from the spectra of the
Co(II)-added enzymes.

Discussion
Even though the crystal structures of most MβL's show proteins with dinuclear Zn(II) metal binding sites, there
are many questions that remain about metal binding to these biomedically important enzymes. For example,
several studies on metallo-β-lactamase BcII from Bacillus cereus indicated that the enzyme contained a highaffinity and a low-affinity metal binding site (19, 24, 45−48), suggesting that metal binding to this MβL would be
sequential. This result was questioned by deSeny et al., who showed that the addition of Co(II) to the
apoenzyme resulted in equal scrambling of the metal ions between the two metal binding sites (49). Wommer
et al. furthered this study to suggest that physiologically relevant metal binding to several MβL's is probably
substrate-dependent and that all MβL's are mononuclear Zn(II)-containing proteins in vivo (50). However, this
hypothesis has recently been challenged by in vivo metal binding/protein expression studies (51). It is thus clear
that many questions remain about metal binding to MβL's.
Previous spectrophotometric titrations of CcrA identified an absorption band that was assigned to a S → Co(II)
ligand-to-metal charge transfer (LMCT) band that increased in intensity as Co(II) was added, from 0.5 to 2.0
equiv (26). Interestingly, activity versus metal content plots showed that CcrA is 83% as active as the fully loaded
enzyme [Co(II)Co(II)-CcrA] with only 1 equiv of Co(II) added. There are a number of scenarios that can explain
these apparently contradictory results. One possibility is that Co(II) distributes between the Zn1 and Zn2 binding
sites as the apoenzyme is titrated with Co(II), resulting in Co(II) [Co(II) in the Zn1 site] and Co(II) [Co(II) in the
Zn2 site] forms of the enzyme, which is the scenario that was predicted for BcII by deSeny et al. (49). This result
would also suggest that either both mononuclear forms of CcrA are nearly fully active or that one form is fully
active and the other is half as active as the fully loaded enzyme. Another possibility that could explain the
previous spectrophotometric titrations and kinetics is that the first metal ion binds to a site that contains metal
ligands from both metal binding sites. When the second metal ion binds, there would have to be a
rearrangement of the metal binding site to accommodate the second metal ion. This form of the enzyme would
have to be very active to account for the activity versus metal content data. One possibility that does not
account for the previous data on CcrA is one with positive cooperativity in metal binding. In this case, CcrA
samples containing 1 equiv of metal ion would consist of one-half fully loaded enzyme and one-half apoenzyme.
Clearly, this possibility cannot adequately explain the activity versus metal content plots. In an effort to probe
metal binding to CcrA, spectroscopic studies were used.
The EPR, EXAFS, and 1H NMR studies reported here clearly indicate sequential, site-specific binding of Co(II) to
our apo-CcrA. The EPR spectrum of 1-Co(II)-CcrA suggests 5/6-coordinate Co(II) in the first metal binding site.

The addition of a second Co(II) results in a distinct EPR signal, also indicative of 5/6-coordinate Co(II), but with
higher conformational flexibility. Further, the signal due to Co1 in 1-Co(II)-CcrA is identical in both form and
intensity to the signal due to Co1 in the spectrum of Co(II)Co(II)-CcrA. These data argue strongly that Co(II)
binding to apo-CcrA is sequential. The signals from Co1 and Co2 exhibit no resolvable I = 7/259Co hyperfine
splittings, consistent with the conformational flexibility anticipated for a site rich in unconstrained ligands, such
as water. In the case of Co1, such a ligand is required, as the activity data of Wang and Benkovic indicate that this
is the hydrolytic metal ion (26). The even greater strain-dependent line widths in the signal from Co2 are
surprising considering the crystal structure of Zn(II)Zn(II)-CcrA (16), as they suggest an even less constrained
ligand sphere, perhaps with a higher number of solvent-derived ligands. These EPR studies do not support the
existence of any spin coupling between the Co(II)'s; however, spin coupling between two metal ions with only
one bridging ligand would be expected to be very weak and not detectable with EPR studies.
The EXAFS suggest 5- or 6-coordination for the first-bound Co(II) ion, consistent with the EPR and UV−vis data
and earlier electronic absorption in the d−d region (26). Multiple-scattering analyses indicate multiple histidine
ligands, suggesting that the first Co(II) binds to the Zn1 site in CcrA. The changes in shape of the outer shell
scattering features for Co(II)Co(II)-CcrA, particularly the appearance of the feature assigned to a 2.5 Å Zn−C
interaction from coordinated aspartate, clearly indicate that the average environment of the cobalt ions is
different from that in 1-Co(II)-CcrA. This observation is inconsistent with nonsequential metal binding, which
would be expected to give the same average structure for both the one- and two-metal forms of the enzyme.
The data for Co(II)Co(II)-CcrA could not unequivocally define a M−M interaction, which we suggest indicates the
absence of a bridging ligand in the di-Co enzyme. This result is consistent with the power and temperature
dependence of the EPR, which showed no exchange coupling between the Co ions in Co(II)Co(II)-CcrA. Since the
crystal structure of CcrA showed a bridging hydroxide and a 4-coordinate Zn1 site and a 5-coordinate Zn2 site
(16), these data clearly indicate that Co(II) does not bind identically as Zn(II) in CcrA. The differing metal ion
environments of the Co(II) versus the Zn(II) enzymes offer an explanation for the lower catalytic activity of the
Co(II)-substituted enzyme, which is a common characteristic of most Co(II)-substituted, Zn(II) metalloenzymes
(39, 52).
Examination of the 1H NMR spectra of one Co-containing and two Co-containing CcrA provides the most
compelling evidence for sequential metal binding to the enzyme. The NMR spectrum of 1-Co(II)-CcrA showed
three solvent-exchangeable proton peaks, assigned to NH protons on Co(II)-bound histidines. The Zn1 site in
CcrA has three metal binding histidines (His116, His118, and His196) (16); therefore, the NMR studies strongly
suggest that the first Co(II) binds in the Zn1 site of the enzyme. The NMR spectrum of Co(II)Co(II)-CcrA exhibits
the same three solvent-exchangeable proton resonances, along with one additional, solvent-exchangeable peak.
Since the Zn2 site in CcrA has one metal binding histidine residue (His263) (16), this result supports our
conclusion that the second Co(II) binds to the Zn2 site. The NMR spectrum of Co(II)Co(II)-CcrA also demonstrates
an interesting new peak at 208 ppm. We cannot unambiguously assign this resonance at this point, although
previous studies have suggested that β-CH2 protons on Co(II)-bound cysteines can be found at resonance
positions greater than 150 ppm (53). Nonetheless, the presence of the same nine hyperfine-shifted resonances
in the spectra of 1-Co(II)CcrA and Co(II)Co(II)CcrA, with seven additional peaks in the spectrum for
Co(II)Co(II)CcrA, provides the strongest evidence for well-ordered and sequential binding of metal ions by CcrA.
One particularly interesting result of these studies is the lack of direct evidence for a cysteine ligand bound to
Co(II) in the EXAFS and UV−vis studies. Recently, crystal structures of BcII demonstrated that Cys221 can be
oxidized to a S-cysteinesulfinic acid or S-hydroxycysteine (54). This same Cys was shown to be oxidized in the
crystal structure of VIM-2 (PDB code 1KO2). The presence of significant amounts of oxidized Cys221 in CcrA
could explain why a S to Co(II) LMCT was not observed in the UV−vis titrations or a S−Co(II) interaction was not
observed in the EXAFS studies on Co(II)Co(II)-CcrA. However, unlike in BcII and VIM-2 where oxidized Cys221 is

probably not a metal binding ligand, CcrA with oxidized Cys221 can bind 2 equiv of metal, suggesting that this
amino acid can potentially coordinate the second Co(II). The observed coordination numbers of Co(II) in 1-Co(II)CcrA and in Co(II)Co(II)-CcrA suggest a high degree of flexibility in the metal binding sites of CcrA and may aid in
reducing steric effects that prevent a second equivalent of metal from binding to BcII and VIM-2 with oxidized
Cys221 residues. This flexibility in the metal binding site of CcrA may allow for coordination of the sulfur of
oxidized Cys221 and lead to the assignment of the 208 ppm resonance in the NMR spectrum to β-CH2 protons
on Co(II)-bound, oxidized Cys221, although, to our knowledge, this scenario would be unprecedented in the
literature. This flexibility in the Zn2 metal binding site could lead to Co(II) binding to the sulfur atom of oxidized
Cys221 in most molecules of CcrA and to the oxygen in others. The resulting mixture of proteins could explain
why some of the NMR signals observed for Co(II)Co(II)-CcrA appear to integrate to less than one proton and why
there are more signals than predicted by the crystal structure (16). As we strictly followed the purification
protocol of CcrA as described by Wang et al. (26), it is not clear why our samples may contain oxidized cysteines
and those previously reported do not. Our preparation of CcrA results in an enzyme that exhibits the same
kinetic properties as previously reported and allows for sequential binding of Co(II), as clearly indicated by our
EPR, EXAFS, and NMR data. The ability to sequentially bind Co(II) to CcrA now allows for the preparation and
characterization of mixed metal analogues of CcrA (Co−CcrA, CoZn−CcrA, ZnCo−CcrA, and CoCo−CcrA) and allows
for the elucidation of the roles of each metal ion in catalysis and substrate binding.
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